NewAmsterdam Pharma Files 8-K

TL;DR

NewAmsterdam Pharma filed an 8-K on Nov 18, 2024, covering financial statements and other events.

AI Summary

NewAmsterdam Pharma Company N.V. filed an 8-K on November 18, 2024, reporting on various events. The filing includes information related to financial statements and exhibits, as well as other events and a Regulation FD disclosure. The company is incorporated in The Netherlands and its principal executive offices are located in Naarden.

Why It Matters

This 8-K filing provides updates on NewAmsterdam Pharma's corporate activities and financial reporting, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news or events.

Key Players & Entities

• NewAmsterdam Pharma Company N.V. (company) — Registrant
• November 18, 2024 (date) — Date of earliest event reported
• The Netherlands (location) — State of incorporation and principal executive offices location
• Naarden (location) — City of principal executive offices

FAQ

Filing Documents

• d840591d8k.htm (8-K) — 54KB
• d840591dex991.htm (EX-99.1) — 36KB
• 0001193125-24-260923.txt ( ) — 262KB
• nams-20241118.xsd (EX-101.SCH) — 3KB
• nams-20241118_def.xml (EX-101.DEF) — 14KB
• nams-20241118_lab.xml (EX-101.LAB) — 23KB
• nams-20241118_pre.xml (EX-101.PRE) — 15KB
• d840591d8k_htm.xml (XML) — 6KB

Forward-Looking Statements

Forward-Looking Statements Certain statements included in this Current Report on Form 8-K that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Company's business and strategic plans, the Company's commercial opportunity, the therapeutic and curative potential of the Company's product candidate, the Company's clinical trials and the timing for enrolling patients, the timing and forums for announcing data, the achievement and timing of regulatory approvals, and plans for commercialization. These statements are based on various assumptions, whether or not identified in this Current Report on Form 8-K, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company's product candidate and the timing of expected regulatory and

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 Press Release, dated November 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Michael Davidson Chief Executive Officer Dated: November 18, 2024

View Full Filing

View this 8-K filing on SEC EDGAR